Hereditary Angioedema — CPB 0782 | AETNA Coverage Update

Aetna modified CPB 0782 for hereditary angioedema (HAE), effective November 15, 2025. Here's what billing teams need to do before that date.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0782 to revise coverage criteria for HAE prophylactic and acute treatment agents. This policy governs HCPCS codes J0593 (lanadelumab), J0596 (Ruconest), J0597 (Berinert), J0598 (Cinryze), and J1290 (ecallantide), along with administration codes like CPT 96365–96376. If your practice manages HAE patients on commercial Aetna plans, this coverage policy change affects your prior authorization workflow and your reimbursement on every one of these drugs.

Quick-Reference Table

Field	Detail
Payer	Aetna, a CVS Health company
Policy	Hereditary Angioedema — CPB 0782
Policy Code	CPB 0782
Change Type	Modified
Effective Date	November 15, 2025
Impact Level	High
Specialties Affected	Allergy/Immunology, Hematology, Internal Medicine, Infusion Centers, Specialty Pharmacy
Key Action	Audit all active HAE prior authorizations against updated criteria before November 15, 2025

Aetna Hereditary Angioedema Coverage Criteria and Medical Necessity Requirements 2025

The Aetna HAE coverage policy under CPB 0782 applies to commercial medical plans only. Medicare members follow separate Part B criteria — do not apply this CPB to Medicare billing.

Precertification is required for all HAE agents. Call (866) 752-7021 or fax (888) 267-3277 to initiate prior authorization. This is not optional — every HAE drug covered under this policy requires it, and missing this step is the fastest route to a claim denial.

Cinryze (C1 Esterase Inhibitor Human, J0598) — Prophylactic Use

Aetna considers Cinryze medically necessary for HAE attack prevention when a specialist in HAE management prescribes it. The member cannot use Cinryze alongside any other HAE prophylaxis medication.

Lab-confirmed C1 inhibitor deficiency path:

#	Covered Indication
1	C1-INH antigenic level below the lab's lower limit of normal; OR
2	Normal C1-INH antigenic level with functional C1-INH below 50% or below the lab's lower limit of normal

Normal C1 inhibitor path (genetic/familial):

#	Covered Indication
1	Confirmed pathogenic variant in F12, angiopoietin-1, plasminogen, KNG1 (kininogen-1), HS3ST6, or MYOF via genetic testing; OR
2	Documented family history of angioedema that failed at least one month of high-dose antihistamine therapy (cetirizine 40 mg/day or equivalent)

Both paths also require that other causes of angioedema — ACE inhibitor-induced, estrogen-related, allergic — have been ruled out. Document this ruling in the chart. Reviewers will look for it.

Cinryze continuation requires all four of these: continued specialist oversight, ≥50% reduction in attack frequency, reduced use of acute rescue medications, and meeting the original initial approval criteria.

Also note: Aetna applies a Site of Care Utilization Management Policy specifically to Cinryze. Check the site-of-service policy before billing infusion administration codes 96365–96368 for Cinryze in any setting other than the one listed on the authorization.

Donidalorsen (Dawnzera) — Prophylactic Use

Dawnzera is a newer oral agent covered for HAE prophylaxis when prescribed by an HAE specialist, used without other prophylactic HAE medications, and when the member meets lab or genetic criteria similar to Cinryze's. The policy was updated to include this agent — if you're billing for Dawnzera before confirming prior authorization under CPB 0782 Aetna criteria, stop and verify first.

Lanadelumab (Takhzyro, J0593) — Prophylactic Use

J0593 is the HCPCS code for lanadelumab-flyo. Aetna lists this as a covered indication under CPB 0782. Medical necessity criteria follow the same specialist-prescriber and lab/genetic confirmation framework as Cinryze.

Acute Treatment Agents — Ruconest, Berinert, Ecallantide

These agents treat acute HAE attacks rather than prevent them. The HCPCS codes are:

#	Covered Indication
1	J0596 — Ruconest (C1 esterase inhibitor, recombinant), 10 units
2	J0597 — Berinert (C1 esterase inhibitor, human), 10 units
3	J1290 — Ecallantide, 1 mg

Coverage applies when selection criteria are met. Document the acute attack, the HAE diagnosis, and the ordering provider's specialty. For acute infusions, administration goes on 96374 or 96375 depending on your billing setup — but check the authorization to confirm site-of-service approval.

Aetna HAE Exclusions and Non-Covered Indications

Aetna considers all indications for Cinryze outside the criteria above experimental, investigational, or unproven. That's a blanket exclusion — any off-label use of Cinryze that doesn't fit the C1 inhibitor deficiency or genetic variant criteria will not get covered.

Combination prophylaxis is also not covered. If a member is already on one HAE prophylactic agent, adding Cinryze, Dawnzera, or lanadelumab as a second prophylactic will trigger a denial. The policy is explicit: these drugs are covered only when used without other prophylaxis medications.

This is where practices get caught. Document in the chart — and in the prior auth request — that the patient is not on concurrent prophylactic therapy.